A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP

Trial Profile

A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2018

At a glance

  • Drugs AG-270 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2018 According to an Agios Pharmaceuticals media release, the first patient from this trial has been dosed.
    • 28 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 15 Feb 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top